AW
FATE icon

Avion Wealth’s Fate Therapeutics FATE Stock Holding History

Avion Wealth’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Buy
858
+233
+37% +$431 ﹤0.01% 1051
2026
Q1 		$0 Hold
625
– – ﹤0.01% 1350
2025
Q4 		$0 Hold
625
– – ﹤0.01% 1342
2025
Q3 		$0 Hold
625
– – ﹤0.01% 1299
2025
Q2 		$0 Buy
+625
New +$726 ﹤0.01% 1299
2023
Q4 		– Sell
-179
Closed – – 1156
2023
Q3 		$0 Buy
179
+83
+86% +$275 ﹤0.01% 922
2023
Q2 		$0 Buy
+96
New +$530 ﹤0.01% 813

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Avion Wealth's FATE Position: Q2 2026 in Review

Avion Wealth increased its Fate Therapeutics (FATE) stake by 37% in Q2 2026, buying an estimated $431 and bringing the position to 858 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

Avion Wealth first reported a position in FATE in Q2 2023 and has held it in 7 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Avion Wealth held 858 shares of Fate Therapeutics worth $2K as of Q2 2026.
  • Avion Wealth bought 233 Fate Therapeutics shares in Q2 2026, an estimated $431.
  • Fate Therapeutics made up ﹤0.01% of Avion Wealth's portfolio in Q2 2026, its #1051 holding.
  • Avion Wealth first reported a position in Fate Therapeutics in Q2 2023 and has held it in 7 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.